We are writing in response to Bill Finley's article from last week discussing the New York Gaming Commission's suspension of Mr. Wayne Potts.
Our company, ReCellerate, developed the product EquiFlow (concentrated protein serum) that was found in Mr. Potts's barn and the basis for his 45-day suspension, for the treatment of Exercise Induced Pulmonary Hemorrhage (“EIPH”) or bleeding.
Last week,the company issued a press release discussing EquiFlow and addressing some of the misunderstanding about the product in the market. We also confirmed that we have no affiliation with Mr. Potts, we never sold him the product and he has never been involved in one of our investigational studies. We would greatly appreciate it if you would publish a follow-up to Mr. Finley's article citing our lack of affiliation with Mr. Potts and providing information about the product.
We have had incredible success with EquiFlow in investigational testing to date. The product has undergone preliminary testing in horses both here and in Dubai, and the results have shown that the product is both safe and effective for the treatment of EIPH or bleeding. Nearly 40 horses have been involved in such studies. Based on this success and other generated safety data, we are pursuing U.S. regulatory approval.
When approved, EquiFlow will likely be the only federally approved alternative to Lasix. Rather than simply reducing the symptoms of EIPH, our product actually treats the condition by facilitating the regeneration of the ruptured vascular wall that is the source of bleeding.
We would appreciate your assistance with informing readers, including trainers, owners and fans about the ReCellerate product.
Best regards,
Karl M. Nobert, ReCellerate, Inc
The post Letter to the Editor: Karl Nobert, ReCellerate, Inc. appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.
